ArticleFrontiers in physiology2018
The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis.
Article in Frontiers in physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Prolactin as a Candidate Biomarker in Non-Small Cell Lung Cancer: Implications for Personalized Medicine and Post-Treatment Risk Stratification.Journal of personalized medicine · 2026Review
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- Circulating Molecular Biomarkers for the Diagnosis and Monitoring of NSCLC-A Review.International journal of molecular sciences · 2025Review
- Liquid biopsy diagnostics for non-small cell lung cancer via elucidation of tRNA signatures.Communications medicine · 2025Article
- Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state.World journal of psychiatry · 2025Article
- Long Non-Coding RNAs as Emerging Targets in Lung Cancer.Cancers · 2023Review
- Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.Journal of clinical medicine · 2022Review
- Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer.Cancers · 2022Article
- Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management.Journal of personalized medicine · 2021Review
- Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer.Scientific reports · 2021Article
- Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array.Frontiers in immunology · 2021Article
- Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Identification of plasma lipid species as promising diagnostic markers for prostate cancer.BMC medical informatics and decision making · 2020Article
- Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article.JNMA; journal of the Nepal Medical Association · 2020Review
- Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.